Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof

A binding protein that binds a polypeptide comprising an immunogenic peptide comprising or consisting of a peptide epitope selected from VLEYVIKV (SEQ ID NO:

• 2), KVLEYVIK (SEQ ID NO:
• 3), and peptide sequences listed in Table 1, optionally wherein the binding protein:
• 1) is an antibody, an antigen-binding fragment of an antibody, a TCR, an antigen-binding fragment of a TCR, a single chain TCR (scTCR), a chimeric antigen receptor (CAR), or a fusion protein comprising a TCR and an effector domain;
• 2) comprises:
• a) a TCR alpha chain variable (Vα) domain comprising CDR1 having at least about 80% identity to residues 48-53 of SEQ ID NO:
• 9 (VSGLRG), CDR2 having at least about 80% identity to residues 71-77 of SEQ ID NO:
• 9 (LYSAGEE), and CDR3 having at least about 80% identity to residues 109-119 of SEQ ID NO:
• 9 (CAVSYGONFVF);
• and
• b) a TCR beta chain variable (Vβ) domain comprising CDR1 having at least about 80% identity to residues 46-50 of SEQ ID NO:
• 11 (SGHTS), CDR2 having at least about 80% identity to residues 68-73 of SEQ ID NO:
• 11 (YDEGEE), and CDR3 having at least about 80% identity to residues 110-123 of SEQ ID NO:
• 11 (CASSLGQLNTEAFF);
• 3) comprises:
• a) a TCR alpha chain variable (Vα) domain with at least about 80% identity to residues 1-130 of SEQ ID NO:
• 9;
• and
• b) a TCR beta chain variable (Vβ) domain with at least about 80% identity to residues 1-133 of SEQ ID NO:
• 11;
• 4) comprises:
• a) a TCR alpha chain with at least about 80% identity to the sequence of SEQ ID NO:
• 9;
• and
• b) a TCR beta chain with at least about 80% identity to the sequence of SEQ ID NO:
• 11;
• 5) comprises:
• a) a T cell receptor (TCR) alpha chain CDR sequence with at least about 80% identity to a TCR alpha chain CDR sequence selected from the group consisting of TCR alpha chain CDR sequences listed in Table 2;
• and/or
• b) a TCR beta chain CDR sequence with at least about 80% identity to a TCR beta chain CDR sequence selected from the group consisting of TCR beta chain CDR sequences listed in Table 2, wherein the binding protein is capable of binding to a MAGEA1 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M;
• 6) comprises:
• a) a TCR alpha chain variable (Vα) domain sequence with at least about 80% identity to a TCR Vα domain sequence selected from the group consisting of TCR Vα domain sequences listed in Table 2;
• and/or
• b) a TCR beta chain variable (Vβ) domain sequence with at least about 80% identity to a TCR Vβ domain sequence selected from the group consisting of TCR Vβ domain sequences listed in Table 2, wherein the binding protein is capable of binding to a MAGEA1 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M;
• 7) comprises:
• a) a TCR alpha chain sequence with at least about 80% identity to a TCR alpha chain sequence selected from the group consisting of TCR alpha chain sequences listed in Table 2;
• and/or
• b) a TCR beta chain sequence with at least about 80% identity to a TCR beta chain sequence selected from the group consisting of TCR beta chain sequences listed in Table 2, wherein the binding protein is capable of binding to a MAGEA1 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M;
• 8) comprises:
• a) a TCR alpha chain CDR sequence selected from the group consisting of TCR alpha chain CDR sequences listed in Table 2;
• and/or
• b) a TCR beta chain CDR sequence selected from the group consisting of TCR beta chain CDR sequences listed in Table 2, wherein the binding protein is capable of binding to a MAGEA1 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M;
• 9) comprises:
• a) a TCR alpha chain variable (Vα) domain sequence selected from the group consisting of TCR Vα domain sequences listed in Table 2;
• and/or
• b) a TCR beta chain variable (Vβ) domain sequence selected from the group consisting of TCR Vβ domain sequences listed in Table 2, wherein the binding protein is capable of binding to a MAGEA1 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M;
• and/or
• 10) comprises:
• a) a TCR alpha chain sequence selected from the group consisting of TCR alpha chain sequences listed in Table 2;
• and/or
• b) a TCR beta chain sequence selected from the group consisting of TCR beta chain sequences listed in Table 2, wherein the binding protein is capable of binding to a MAGEA1 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.